Investor Centre

Our broad clinical and preclinical pipeline in oncology and behavioural brain disorders focuses on indications including glioblastoma, neurodevelopmental disorders, addiction, anxiety, fatigue and narcolepsy.
Stat background
0.75 GBX Volume: Market Capitalisation (m) £3.21

TheraCryf plc Full Year Results

29 - May - 2024
Current corporate presentation

Voting on AGM Resolutions

18 - July - 2024
Results of voting on resolutions following TheraCryf's AGM held on Thursday 18th July 2024.

TheraCryf plc - Research and Development Update

14 - June - 2024
TheraCryf plc present an update on the Company including current status of R&D projects.

Major Shareholder

Current ShareholderNumber of sharesPercentage holding
J. R. Kight34,600,000 8.10%
Rathbones Investment Management Ltd25,789,2466.03%
First Equity Limited25,700,0006.01%
Octopus Investments21,875,0005.12%
Vulpes Investment Management Pte Ltd20,554,1914.81%
Seneca Partners Limited16,301,4563.81%
The number of ordinary shares in issue is 427,346,895 all of which are in public hands. The Company does not hold any shares in Treasury.
Last updated 17 July 2024